Several PDE10A inhibitors have entered Phase I and II clinical trials for non-oncologic indications, such as schizophrenia (ClinicalTrials.gov Identifiers: NCT00570063, NCT02477020, NCT02019329, NCT01568203), and have shown favorable safety profiles (228). The gene discussed is PDE10A; the disease is schizophrenia.